Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy

2026-02-18 08:16:36 ET

Nektar Therapeutics (NKTR) is a clinical-stage biopharmaceutical company focused on developing novel immunology therapies for autoimmune and chronic inflammatory diseases, founded in 1990. The company utilizes proprietary technology platforms, including PEGylation, to create drug candidates that modulate immune system imbalances. Its lead candidate is rezpegaldesleukin (REZPEG), a regulatory T cell stimulator in clinical studies for atopic dermatitis (AD), alopecia areata, and type 1 diabetes....

Read the full article on Seeking Alpha

For further details see: